Zymeworks

Historical price data

Zymeworks Inc. is a global biotechnology company committed to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics. Its core expertise lies in protein engineering, with platforms like Azymetric™ for bispecific antibodies and ZymeLink™ for antibody-drug conjugates enabling a robust pipeline of oncology candidates. The company leverages a dual strategy of advancing its own clinical programs, such as zanidatamab, while entering into significant collaborations with major pharmaceutical firms to broaden the impact of its technology.

Integrated suite of protein engineering platforms including Azymetric™ for bispecific antibodies and ZymeLink™ for antibody-drug conjugates (ADCs), enabling the design of multifunctional biotherapeutics with optimized properties.

7 drugs in pipeline, 1 in Phase 3

Total raised: $282M

Zymeworks faces competition from large pharma (Roche, AstraZeneca/Daiichi Sankyo) in the HER2 space and from other biotechnology platform companies (Genmab, AbCellera). Its differentiation lies in its unique biparatopic bispecific mechanism for zanidatamab and its integrated, modular technology platforms capable of generating both bispecific antibodies and ADCs.